Bivalent IAP antagonists inhibit TRAF2-bound cIAPs and limit TNF-mediated NF-κB signaling.
TetraLogic Pharmaceuticals Corporation, 343 Phoenixville Pike, Malvern, PA 19355, USA.
Stephen M
SM
Condon
D000818:Animals; D002460:Cell Line; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000037:antagonists & inhibitors*; D016328:NF-kappa B / Q000378:metabolism*; D011485:Protein Binding / Q000187:drug effects; D015398:Signal Transduction / Q000187:drug effects; D047992:TNF Receptor-Associated Factor 2 / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*
D051034:Inhibitor of Apoptosis Proteins; D016328:NF-kappa B; D047992:TNF Receptor-Associated Factor 2; D014409:Tumor Necrosis Factor-alpha
Nat Commun. 2015 Aug 03;6:7956
26234182
Sci Transl Med. 2016 May 18;8(339):339ra69
27194727
Cancer Cell. 2016 Feb 8;29(2):145-58
26859455
Sci Transl Med. 2016 May 18;8(339):339ra70
27194728
J Med Chem. 2014 May 8;57(9):3666-77
24684347
Blood. 2014 Apr 17;123(16):2562-72
24497535
Biochem J. 2012 Nov 1;447(3):427-36
22853455
Nat Commun. 2015 Feb 18;6:6282
25693118
Cancer Cell. 2016 Apr 11;29(4):494-507
27070702
Proc Natl Acad Sci U S A. 2015 May 5;112(18):5803-8
25902530
Cell Death Discov. 2017 Jan 16;3:16046
28149532
Mol Cancer Ther. 2014 Apr;13(4):867-79
24563541
J Exp Med. 2010 Sep 27;207(10):2195-206
20837698